BioSig Technologies, Inc. (BSGM)
OTCMKTS: BSGM · Delayed Price · USD
0.350
0.00 (0.03%)
Jul 2, 2024, 3:58 PM EDT - Market closed
BioSig Technologies Revenue
BioSig Technologies had revenue of $27.00K in the twelve months ending March 31, 2024, down -90.46% year-over-year. Revenue in the quarter ending March 31, 2024 was $14.00K with 180.00% year-over-year growth. In the year 2023, BioSig Technologies had annual revenue of $18.00K, a decrease of -93.71%.
Revenue (ttm)
$27.00K
Revenue Growth
-90.46%
P/S Ratio
183.12
Revenue / Employee
$6,750
Employees
4
Market Cap
4.94M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 18.00K | -268.00K | -93.71% |
| Dec 31, 2022 | 286.00K | -155.00K | -35.15% |
| Dec 31, 2021 | 441.00K | - | - |
| Dec 31, 2020 | 0 | - | - |
| Dec 31, 2019 | 0 | - | - |
| Dec 31, 2018 | 0 | - | - |
| Dec 31, 2017 | 0 | - | - |
| Dec 31, 2016 | 0 | - | - |
| Dec 31, 2015 | 0 | - | - |
| Dec 31, 2014 | 0 | - | - |
| Dec 31, 2013 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 379.49B |
| Johnson & Johnson | 81.80B |
| Merck & Co. | 61.40B |
| AbbVie | 54.40B |
| Novartis AG | 49.92B |
| AstraZeneca | 47.61B |
| Thermo Fisher | 42.49B |
| Abbott Laboratories | 40.33B |
BSGM News
- 22 days ago - BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer - GlobeNewsWire
- 4 weeks ago - BioSig Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 6 weeks ago - BioSig Technologies Chief Executive Officer Mr. Anthony Amato Issues the Following Letter to Shareholders - GlobeNewsWire
- 2 months ago - BioSig Technologies, Inc. Announces New Appointments to its Now Fully Constituted Board of Directors, which is Comprised of 5 Board Members, 3 Independent - GlobeNewsWire
- 2 months ago - BioSig Technologies, Inc. Appoints Mr. Anthony Amato to Position of Chief Executive Officer, Effective Immediately - GlobeNewsWire
- 3 months ago - BioSig Engages Consulting Firm for Business Model Strategies - GlobeNewsWire
- 4 months ago - BioSig Announces Reduction of its Workforce - GlobeNewsWire
- 5 months ago - BioSig's PURE EP™ Platform with New Near Field Tracking Algorithm Surpasses 100 Patient Cases - GlobeNewsWire